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Editorial Comment
Angioplasty Therapy of
Cardiogenic Shock: Are
Randomized Trials Necessary?*
WILLIAM W. O'NEILL. MD. FACC
Royal Oak, Michigan
In 1954. Griffith cc al. (1) reported an SOS% in-hospital
mortality rate for patients with cardiogenic shock after acute
myocardial infarction . Thirty-five years later . despite dra-
matic advances in cardiac care. Goldberg et al . (2) found no
improvement in this dismal prognosis
. Cardiogenic shock
has been refractory to such major advances as coronary care
unit (CCU) management (3), intraaortic balloon counterpul .
sation (41 and emergency coronary bypass surgery (5). Even
after the revolution in care brought about by thrombolytic
therapy, cardiogenic shock still has a dismal prognosis
.
Treatment with intracoronary streptokinase
(6) .
intravenous
streptokinase Mill and intravenous recombinant tissue-type
plasminogen activator (91 has failed to improve outcome,
The present study . Given the high mortality rate with
conventional care, the 56% survival rate reported in this
issue of the Journal by Moosvi and colleagues (10) is
encouraging
. These investigators found that the 32 patients
with successful revaseularization had a greater likelihood of
survival than did the 49 patients treated without revascutar-
itation . Furthermore . patients undergoing revascutarization
within 24 h of the onset of shock had a 77% survival rate.
These heartening results must he tempered by the major
deficiencies in the trial design of the study .
First, the observations are based on retrospective chain
review. Second, the investigators
0W do not clearly define
their criteria for the selection of some patients for aggressive
therapy and others for conventional care . This lack suggests
that case selection bias partly explains the favorable results
reported . For example, intraaonic balloon support was
provided to 94%a of the revascularization group but to only
39%a of the conventional therapy group . These differences in
management raise the possibility that aggressive care was
offered to the patients who were the most fit and thus the
most likely to survive
. Despite these limitations. this study
(10) provides clinicians with useful clues for managing pa-
tients with cardiogenic shock . Most important . the investi-
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wor, (10) carefully defined cardiogenic shack with accepted
criteria . It is therefore possible to compare their results with
those of other reported sells
.
Previous reports
. To doe, 10 grooms (10-191 including
that of Mv.»ai el al .
(10) have evaluated treatment of
cardiogenic shock with coronary angicplasty (lab€e 1)
.
Among the 327 patients studied, the cumulative survival rate
is 59
r
%r :
64% have had successft-1 repe fusion . suial,al is
clearly linked to repcrfusion status
. The probability of sur-
vival is 73% in patients with successful
",perfusion
but only
2210 in patients with unsuccessful reperfusion . Review of
these reports suggests that subgroups of patients with shock
.^
.rc most likely to benefit from this aggressive therapy .
Moosvi et al . (10) clearly demonstrate the role of early
reperfusiou in improving survival probability . DrWood et at .
(20) previously demonstrated a 60h survival rate for patients
with cardiogenic shock treated with early bypass surgery .
Early therapy appears crucial but ongoing necrusis lasting
many hours (211 appears to occur after cardiogenic shock .
For this reason, therapy up to 24 h after symptom onset may
be efficacious . Further review of the published series (10-19)
suggests that patients with severe three-vessel disease do not
greatly benefit from coronary angioplasty . Lee et al. (12)
found that 83% of patients who died after interventional
therapy had severe multivessel disease
. Finally, age appears
to affect prognosis
. We have yet to treat successfully a
patient with severe cardiogenic shock who was >75 years
old. In our institution we now believe that aggressive inter-
vention is contraindicated in the extremely aged patient with
cardiunesic shuck .
Are randoesstrrafitriuls necessary? Given the accumulating
evidence of the benefit of coronary angioplasty in patients
with myocardial infarction and shock, fire randomized trials
necessary in this group? Such fundamental advances as
CCU care
. internal mammary artery implantation and heart
transplantalion have never been subjected to randomized
clinical trials. One could argue that the consistently encour-
aging reports of angioplasty therapy-and the knowledge
that patients in a control group would have a 90% chance of
early death-make a randomized trial unethical . We (22)
attempted to conduct a prospective randomized clinical trial
of thrombolysis and angoplasty in shock (TACS) in 1985 .
Over a 14-month period, 10 active interventions] centers
could recruit only nine patients into this study, largely
because of clinician reluctance to randomize patients to it
nonaggressive strategy
. Again, one must ask whether ran-
domized trials are ethical or feasible in this condition .
As a clinician and clinical researcher deeply interested in
cardiogenic shock
. I believe that randomized trials of ther-
apy of this condition are mandatory . I am troubled that only
reports of treatment with a positive outcome are being
published. Furthermore, aggressive intervention with the
attendant vascular manipulation, contrast medium load and
risk of reperfusion arrhythmia- may actually harm margin .
ally compensated patients . However, 1 also believe that
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Table L Impact of Coronary Angioplasty on Survival in Cardiogenic Shock in 10 Reported Studies
NR - not rcpnr4 1
much more information is required about case selection,
adjunctive supportive therapy and the role of emergency
bypass surgery before prospective randomized trials are
conducted. This information can be gathered most quickly
and eMlciently by a prospective multicenter registry . The
National Heart, Lung, and Blood institute-sponsored bat-
loon velvuloplasty registry and the industry-sponsored reg-
istry of supported angioplasty are superb models for such a
registry. We need to determine the proportion of patients
who
are actually eligible for coronary angioplasty and the
subgroups that are most likely to benefit . Once optimal
aggressive treatment strategies are defined, randomized
trials can be more intelligently designed .
Conclusions. Given our present state of knowledge, we
face a dilemma in the management of cardiugenic shock .
Conventional care is futile ; aggressive care is promising but
nut validated
. For young patients presenting early and
without other terminal comorbidities, I would act on the side
of aggressive intervention . I would treat the extremely aged
with comfort measures only . If aggressive intervention is
selected, patients should be referred to centers experienced
in interventional therapy of
cardiugenic shock . Preferably
those centers should have emergency surgery available and
access to cardiac transplantation and cardiac support de-
vices . Until randomized trials are performed, centers per-
forming interventional therapy must carefully and compre-
hensively collate and publish their results
. Such centers
should be encouraged to enter into the multicenter registry
of cardiogenic shock that is now being planned .
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